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Available online 27 September 2013Background: Evidence suggests that periodontitis is associated with prevalent and incident type 2
diabetes mellitus (T2DM), raising the question of whether periodontitis treatment may improve
glycemic control in patients with T2DM. Meta-analyses of mostly small clinical trials suggest that
periodontitis treatment results in a modest reduction in glycosylated hemoglobin (Hb) A1c.
Purpose: The purpose of the Diabetes and Periodontal Therapy Trial (DPTT) was to determine if
periodontal treatment reduces HbA1c in patients with T2DM and periodontitis.
Methods: DPTT was a phase-III, single-masked, multi-center, randomized trial with a planned
enrollment of 600 participants. Participants were randomly assigned to receive periodontal
treatment immediately (Treatment Group) or after 6 months (Control Group). HbA1c values and
clinical periodontal measures were determined at baseline and 3 and 6 months following
randomization. Medication usage and dosing were assessed at each visit. Periodontal treatment
consisted of scaling and root planing for a minimum of two 90-minute sessions, plus the use of an
antibacterialmouth rinse for at least 32 days afterwards. The primary outcomewas change inHbA1c
from baseline to 6 months and the trial was powered to detect a between-group difference of 0.6%.
Secondary outcomes included changes in periodontal clinical measures, fasting plasma glucose, the
Homeostasis Model Assessment (HOMA2) and the need for rescue diabetes or periodontal therapy.
Conclusion: Dental and medical researchers collaborated to recruit, treat and monitor participants
with two chronic diseases to determine if treatment of one condition affects the status of the other.
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Type 2 diabetes mellitus (T2DM) is a growing public health
concern worldwide. Since 2008, diabetes has ranked as the
seventh leading cause of death in the United States[1], with
estimated annual direct costs of $245 billion [2]. Today,
approximately 20.4 million U.S. adults have diabetes, with a
third of all cases undiagnosed [3].A license.
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hyperglycemia [4], which initiates chemical and molecular
pathways associated with diabetes complications [5]. Accord-
ingly, diabetes-related health care expenditures increasewith
decreasing glycemic control [6]. It is estimated that for each
successive 1% increase in HbA1c above 6%, medical care costs
increase by, respectively, 4%, 10%, 20% and 30% [7]. Thus,
establishing and maintaining adequate glycemic control is an
important means of reducing the morbidity, mortality and
medical care costs associated with diabetes.
Periodontitis, a common bacteria-induced, oral inflamma-
tory condition that destroys the supporting structures of the
teeth [8], is associated with diabetes. Individuals with diabetes
are about two and a half timesmore likely to have periodontitis
than medically healthy controls [9]. Periodontitis also is more
severe in those with than without diabetes [10,11] and the
disease tends to be most severe in patients with the poorest
glycemic control [12]. Because of its consistent and severity-
dependent association with diabetes, some have argued that
periodontitis should be consideredmore formally as a diabetes
complication [13].
Infections are known to adversely affect glycemic control
[14]. Emerging evidence suggests that periodontal disease
too may affect glycemia and risk for incident T2DM [15]. The
mechanisms by which periodontitis may affect diabetes risk
are not well established. A common hypothesis poses that
periodontal inflammation and pathogenic bacteria and their
byproducts trigger the production of cytokines, acute phase
proteins and oxidative stress molecules that over time impair
insulin sensitivity or action [16].
Because of the proposed bidirectional relationship between
T2DM and periodontitis, researchers have studied whether
periodontal treatment improves metabolic control in patients
with T2DM. At the time the Diabetes and Periodontal Therapy
Trial (DPTT) was being planned (early 2007), all published
trials of T2DM were small, some lacked controls, and none
was multi-centered. A meta-analysis of five published trials
reported a decrease in HbA1c of 0.66% following periodontal
therapy [17]. Only one trial, which was published after the
meta-analysis, enrolled more than 100 participants, and that
trial showed no significant effect of periodontal treatment
on HbA1c [18]. Then and now, the research community has
recognized the need for data from large, high-quality, multi-
centered RCTs as the basis for clinical practice recommenda-
tions [17].
Given sufficient biological rationale, initial evidence from
observational studies and small RCTs, and a compelling public
health need to justify a Phase III RCT to evaluate the effects of
periodontal treatment on glycemic control in patients with
T2DM and periodontitis, the Diabetes and Periodontal Therapy
Trial (DPTT) was developed.2. Research design and methods
2.1. Aim and design
DPTT's aim was to determine the effect of non-surgical
periodontal therapy on HbA1c in individuals with T2DM
and chronic periodontitis when compared to no therapy.
We hypothesized that participants receiving therapy wouldexperience a 0.6% greater reduction in HbA1c when compared
to untreated controls.
The DPTT was a single-masked, multicenter, randomized,
controlled, Phase III clinical trial. Participants with moderately-
controlled diabetes and moderate to advanced periodontitis
were randomly assigned to receive immediate or delayed
periodontal treatment. Participants were evaluated at baseline
and at 3 and 6 months following randomization for multiple
measures of diabetes control and periodontitis.
The trial was designed as a single-masked trial, with only
the periodontal examiner masked to treatment assignment.
Double masking would have required us to provide some
type of “sham” periodontal therapy to control participants,
which, to the best of our knowledge, had not been done in
any previous trial in periodontology. An endpoint of treat-
ment is the complete removal of hard and soft deposits from
the tooth and root surfaces. Thus it is not possible to mask
therapists. Periodontal therapy also frequently results in
gingival (gum) recession and tooth sensitivity, especially to hot
and cold temperatures. Treatment also removes the discolored
calcified deposits that form at and just beneath the gum line.
These signs and symptoms, which can be readily noticed by
patients, would not be expected following some type of “sham”
treatment. Thus, it is unlikely that the provision of a sham
treatment would adequately mask control participants either.
The trial was led by a study chair (SE), who headed the
trial's Executive and Steering Committees. An independent
Coordinating Center (CC) trained and certified site study
personnel, developed the Manual of Operations and data
collection forms, monitored trial activities, and processed and
will analyze trial data. A central Core Laboratory performed
the blood and biochemical tests and transmitted the results
directly to the CC. A Data and Safety Monitoring Board
reviewed study conduct and participant safety.
Clinical site selection was based on: 1) the clinical
research experiences and collaborative history of site inves-
tigators; 2) access to a large numbers of patients with T2DM;
3) some geographic diversity within the United States; and
4) the presence of local facilities and personnel to conduct
detailed periodontal examinations and collect, process and store
blood samples. The number of clinical sites was based on the
projected sample size, the timeline for recruitment, and the
sites' expected cumulative enrollment rate. Four clinical sites
were proposed as part of the initial grant application; three
were funded by the sponsor. Clinical sites were established first
in Alabama (University of Alabama at Birmingham), Minnesota
(University of Minnesota and Hennepin CountyMedical Center,
both in Minneapolis) and Texas (University of Texas Health
Science Center at San Antonio). Since recruitment was more
challenging than expected and was lagging behind projections,
two additional clinical sites (at Stony Brook University in New
York and the University of Texas Health Science Center at
Houston) were added later. These additional sites were selected
based on similar criteria used for the initial sites as well as their
potential to become certified and begin enrolling participants
relatively quickly.
2.2. Study outcomes
The trial's primary outcome was change in HbA1c from
baseline to the 6-month post-randomization visit. We selected
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diabetes status [19], is associated with risk for diabetes-related
complications [20], andwas the primary outcome used inmany
previous trials in periodontology [21].
Secondary outcomes included:
• HBA1c change from baseline to the 3-month visit
• Change in clinical measures of chronic periodontitis (gingival
index, bleeding on probing, probing depth, clinical attach-
ment loss) at 3 and 6 months
o Probing depth, clinical attachment loss and bleeding on
probing are standard clinical measurements used to
assess individual's periodontal condition. The gingival
index estimates gingivitis severity.Box 1
DPTT inclusion and exclusion criteria.
Inclusion criteria
1. At least 35 years of age and able to provide informed co
2. Physician diagnosed type 2 diabetes of more than three m
3. Currently under the care of a physician for diabetes mana
4. Screening HbA1c value N7% and b9%.
5. No change in diabetes-related medications* during the th
6. Willingness to provide consent to contact treating phy
diabetes-related medications during the trial†
7. Moderate to severe chronic periodontitis, defined as loss
more tooth sites in each of 2 or more quadrants
8. Ability and willingness to cooperate with the study proto
9. No definitive periodontal treatment during the six months
10. Likely to have at least 16 natural teeth for trial duration.
11. Willingness to avoid pregnancy during study participation
* Change was defined as any of the following: change in dose of
dose of insulin of more than 10%; addition or subtraction of an
†Changes were allowed if overt symptoms developed (e.g., po
blood glucose was 240 mg/DL or higher.
Exclusion criteria
1. Self-reported serious concurrent disease that, in the opini
than 1 year.
2. Emergency room or physician visit within the last
complications.
3. Chronic or continuous use (daily for more than 7 days) of
2 months, other than low dose aspirin (e.g., 75–325 mg
4. Receiving chronic treatment with systemic corticostero
drugs.
5. Chronic treatment with systemic antibiotics (antibiotics f
6. Currently receiving dialysis.
7. At increased risk of bleeding complications from dental t
8. Requiring essential dental care (e.g., treatment for grossly
infections, other dental infections)
9. Heavy alcohol consumption (on average N2 drinks/day fo
10. Currently pregnant or considering becoming pregnant wi
11. Any other criterion that, in the opinion of the investigator
compliance• Change in fasting glucose, the Homeostatsis Model Assess-
ment (HOMA2), and diabetes medications from baseline
o The Homeostasis Model Assessment 2 (HOMA2) estimates
steady-state beta cell function and insulin sensitivity from
insulin and glucose measurements. HOMA2 values corre-
late well with results from euglycemic-hyperinsulinemic
clamp studies [22].
• Need for diabetes and periodontal rescue therapy
2.3. Eligibility
The trial's inclusion and exclusion criteria are listed in
Box 1. These criteria were selected to maximize the chance
that a participant would complete the 6-month trial andnsent.
onths duration.
gement.
ree months prior to enrollment.
sician and physician agreement to refrain from changing
of clinical attachment and probing depth≥5 mm at two or
col and attend all study visits.
prior to enrollment.
.
any 1 hyperglycemic drug by more than two-fold; change in
oral hyperglycemic agent or insulin.
lydipsia, polyuria), HbA1c was 9.5% or higher or fasting
on of the referring physician, limited life expectancy to less
30 days because of hyperglycemia or diabetes-related
nonsteroidal anti-inflammatory drugs within the preceding
/day).
ids, cyclosporine or other systemic immunosuppressive
or N6 days within 30 days of baseline visit).
reatment, based on medical history.
decayed teeth, broken teeth, dental abscesses, peri-apical
r women and N3 drinks/day for men)
thin the 6-month follow-up period
, would preclude study completion or limit the participant’s
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kidney failure and immunosuppressive therapy, on a
participant's periodontal treatment response or medical man-
agement during the trial. We targeted individuals whose
glycemia was not well controlled despite being under the
regular care of a physician for T2DM. To minimize the number
of diabetesmedication changes during the trial, we set the upper
limit for screeningHbA1c values atb9% and excluded individuals
with physician-directed medication changes within 3 months
prior to randomization. The lower limit for HbA1c (≥7.0%) was
chosen to increase the probability that a participant's HbA1c
could be reduced with periodontal treatment by 0.6%. Partici-
pants taking non-steroidal anti-inflammatory drugs for more
than 7 consecutive days within the previous 2 months were
excluded because this class of drugs may lower HbA1c [23].
We required participants to have moderate to advanced
periodontitis at two or more tooth sites in each of two or
more quadrants in the mouth (See Box 1). The deepened
(≥ 5 mm)probingdepth and clinical attachment lossmeasures
had to be present at the same location (site) on a tooth. The
qualifying sites in a quadrant, however, could be located on the
same tooth. Notably, periodontal disease eligibility criteria in
previous clinical trials have varied considerably, which may
explain the heterogeneity in these trial results [24]. DPTT's
periodontal eligibility criteria were similar to those of at least
two previous trials [25,26] and were generally based on the
joint Center for Disease Control and Prevention (CDC) and
American Academy of Periodontology (AAP)'s definition of
“moderate” periodontitis [27]. Compared to the CDC/AAP
definition, we used a higher threshold for clinical attachment
loss (≥ 5 mm versus≥ 4 mm, indicatingmore severe disease),
required that the clinical attachment loss and probing findings
be on the same tooth site, and required there to be affected
teeth in at least two (versus one) dental quadrants.
2.4. Recruitment
Because eligibility was based on features of two diseases,
recruitment required broad and novel efforts. Participants were
recruited from medical and dental clinics, through referrals
from community medical practices, using posted flyers, bro-
chures and educational materials, through radio and print
advertisements, and through investigator appearances on local
television or radio stations. We also established relationships
with off-site dental and diabetes clinics, community groups and
places of worship that serve high-risk patient populations,
including African–Americans, Hispanics and Native Americans,
and senior communities. Some affiliated medical clinics
identified patients with recent HbA1c values near the study
range and mailed Institutional Review Board (IRB)-approved
recruitment materials to potentially eligible patients.
2.5. Prescreening and screening
Dentists often are unaware of the details of their patient's
diabetes status and management [28], and physicians typically
do not assess their patients' periodontal condition. Thus, we
prescreenedparticipants referred frommedical clinics for dental
eligibility, and vice versa. In addition, patients with untreated
periodontal disease frequently have untreated caries (decay or
cavities)[29] or abscessed teeth. Because we sought to isolatethe effects of periodontal treatment alone on HbA1c, we also
screened for and excluded individuals with non-periodontal
essential dental care needs (e.g., untreated gross caries or
abscessed teeth).
Recruiters or Clinic Coordinators initially assessed an
individual's eligibility via phone or in person using an IRB-
approved questionnaire. Individuals were asked about their
recent medical and dental history, use of prescription and
over-the-counter medications, and number of remaining
natural teeth. Potentially eligible and interested individuals
were scheduled for an in-person screening visit.
Participants provided written consent at the start of the
screening visit. IRB-approved Spanish translations of the
study forms were available for use. Certified interpreters
also were available for non-English speakers at the time of
consent and throughout the trial. Participants completed a
medical/dental history questionnaire, received a dental and
abbreviated periodontal examination, and provided a blood
sample for HbA1c testing. Eligibility was based on the
screening HbA1c value. (A participant's HbA1c measurement
at baseline (see below) was used as the baseline study value,
but not to reconfirm eligibility.)
Dental radiographs were obtained to verify alveolar bone
loss and detect non-periodontal oral infections (e.g., dental
caries and abscessed teeth). Individuals who appeared to
meet the eligibility criteria at screening were scheduled for
a baseline visit. Otherwise eligible participants who had
non-periodontal essential dental care needs were referred
for treatment and offered to be rescreened once these needs
were addressed.2.6. Data collection
Trained and certified study personnel collected data
and blood samples using standard procedures to assess a
participant's baseline periodontal and diabetes statuses and
to track changes in each condition during the trial. Table 1
summarizes the data and blood collection by study visit. A
participant's flow through the trial is depicted in Fig. 1.
Trained personnel interviewed participants at each study
visit (Baseline, 3- and 6-months). Participants self-reported
race and ethnicity, smoking/tobacco and alcohol use, daily
exercise, dietary and dental history, education, employment,
health insurance coverage, oral hygiene habits, and self-
perceived overall and oral health, medical history and medica-
tion use. To enhance accuracy of medication reporting, partic-
ipants were asked to bring their medications to each study visit.
Study personnel reviewed the medications with the participant
to record accurate dosing information. Study personnel mea-
sured blood pressure (in mm Hg), height (in m) and weight
(in kg) in duplicate using calibrated equipment. The CC provided
the same measurement devices to all sites to standardize the
data collection process (Fig. 1).
Datawere recorded on standardizedpaper case report forms.
Completed forms were scanned and transmitted to the CC
through a secure electronic portal (SharePoint, Microsoft,
Redmond, WA). The CC reviewed the forms, prepared edit
statements as needed, and entered the data into Velos eResearch
(Velos, Inc., Fairmount, CA) using double data entry with an
adjudication process. Data were stored in an Oracle database
SCHEMATIC OF DPTT STUDY DESIGN 
Prior to     
Enrollment/ 
Eligibility 
Assessment 
Schedule baseline visit for eligibility 
Baseline 
Visit
Treatment 
Visit (s) 
3 month Visit 
± 2 weeks 
post- 
randomization 
6 month Visit 
± 2 weeks 
Obtain informed consent for screening. Obtain history to determine presence/duration of 
diabetes, current diabetes medication usage and information related to eligibility criteria. 
Perform pregnancy test if required.  Screen subjects to determine level of periodontal 
disease and obtain bloods to determine HbA1c.   
Collect fasting blood for assays; Collect complete periodontal data.   
Deliver non-surgical periodontal therapy to any participant needing rescue therapy.
Deliver maintenance therapy to participants in Treatment Group. 
Deliver non-surgical periodontal therapy to all participants in Control Group who did not 
receive rescue therapy.
Collect fasting blood for assays;  
Collect complete periodontal data
Assessment of Final  
Study Outcomes  
Obtain informed consent for study. Perform pregnancy test and collect fasting blood for 
assays.  Collect complete periodontal data, additional medical history, measure blood 
pressure, pulse, height and weight, complete medication usage.   Independent confirmation 
of eligibility. Contact treating physician to request that participants’ diabetes medications 
remain unchanged during DPTT participation except for patient safety issues.   
Provide oral hygiene and healthy lifestyle information.
Deliver non-surgical periodontal 
therapy 
Treatment Group  
300 participants 
Non-surgical periodontal  
therapy and chlorhexidine 
rinse 
Control Group  
300 participants 
Delayed non-surgical 
periodontal therapy  
≤ 35 
days 
≤ 42 days 
Randomize 
Adverse events monitoring call 2-3 
weeks after baseline visit
Adverse events monitoring call 2-
3 weeks after treatment visit(s) 
Fig. 1. Schematic of DPTT study design.
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(Cary, NC) for analysis.
2.7. Blood collection and processing
Venous blood samples were obtained to assess a variety
of diabetes-related variables, as described below, at each
study visit. Samples collected at screening were non-fasting;
thereafter samples were obtained following 8–12 h of
fasting. HbA1c was assessed at each visit from fresh whole
venous blood collected in tubes containing EDTA. Thebaseline visit was completed within 35 days of the qualifying
screening visit. Because eligibility was based on the screening
HbA1c values, a relatively short time interval was chosen to
minimize the likelihood of changes in HbA1c between the
screening and baseline visits. All blood samples were either
shipped within 4 days to the Core Laboratory (for HbA1c
assessment) or processed and frozen at −70 °C for subse-
quent assessments of glucose, insulin, lipids and creatinine
(Section 2.8). Approximately once a month, the frozen serum
and plasma samples were shipped overnight on dry ice to the
Core Laboratory for storage and analysis.
520 S. Engebretson et al. / Contemporary Clinical Trials 36 (2013) 515–5262.8. Outcome assessments
2.8.1. Primary outcome: HbA1c
HbA1c was measured by the Core Laboratory using an
automated high performance liquid chromatography method
(Tosoh HPLC G7 Glycohemoglobin Analyzer, Tosoh Medics,
Inc., San Francisco CA). The method was calibrated against
National Glycohemoglobin Standardization Program (NGSP)
standards, with a reference range of 4.3–6.0%. The laboratory's
coefficient of variation (CV) ranged from 1.4 to 1.9%. All
laboratory personnel were masked to a participant's group
assignment.
2.8.2. Periodontal assessments
Calibrated and masked examiners assessed participants at
the baseline and 3- and 6-month visits. Measures of dental
plaque and gingivitis [30] were assessed at six locations
(mesiobuccal, mid-buccal, distobuccal, distolingual, mid-lingual
andmesiolingual sites) on each of six “index” teeth [31].MissingTable 1
Schedule of study activities by visit.
Study visits/trial phases
Screening Baseline exam T
Activity Recruitment/
pre-screening
Screening Baseline/
randomization
T
v
v
−35 days
to Day 0
Day 0 0
Consent
Verbal informed consent X
Written informed consent X X
Data collection
Recruitment interview X
Collect and enter
contact information
at recruitment and
screening
X X
Screening visit X
Collect health care
provider information
X
Pregnancy test X X X
Oral/periodontal examination Xa X
HbA1c assessment X X
Essential dental care referral X X
Collect demographic/medical
data and study
measurements
X
Document current
medication use
X
Draw fasting blood sample,
isolate and store serum
and plasma
X
Confirm of eligibility/
randomize
X
Periodontal therapy X
Supportive maintenance
therapy
Periodontal rescue therapy
Diabetes rescue therapy
Post treatment/baseline
telephone follow-up
a Partial exam at screening.index teeth were substituted with adjacent teeth in a pre-
specifiedmanner. Probing depth (PD, inmm), the distance from
gingival margin to the cementoenamel junction (GM–CEJ, in
mm), and bleeding following probing (BOP, scored as present
or absent) were assessed at the same locations on all teeth,
excluding third molars, using a manual periodontal probe
(UNC–15, Hu-Friedy Mfg. Co., Chicago IL). Clinical attachment
loss (CAL) was computed chair-side from the PD and CEJ–GM
for immediate clinical interpretation. The CC also calculated CAL
by computer for use in the analyses and to aid the clinical sites
in identifying progressing sites. Whenever possible, the same
examiner completed all examinations for a participant. Alveolar
bone height was assessed from orthopantomographic radio-
graphs obtained at baseline but was not used to determine
eligibility (Table 1).
A single “gold standard” examiner (SE) trained and cali-
brated the clinical examiners using established standards
[32] with some modifications. The trial standards required
exact or close agreement between examiners (i.e., comparedreatment & follow-up contacts Final visit Post-final visit
reatment
isits 2–4
isits
Follow-up
phone call
3 month
follow-up
6 month
follow-up
Delayed
periodontal
therapy
–42 days 2–3 weeks
Post
treatment/
baseline
3 months ±
2 weeks
6 months ±
2 weeks
(Control Group)
0–28 days post
6 month visit
X X
X X
X X
X X
X X
X X
X
Treatment
Group
Treatment
Group
As needed Referral
As needed
X
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gingivitis assessments, examiners were required to achieve
≥75% and 70% exact agreement within and between examiners,
respectively, and ≥95% agreement within 1 index unit, both
within and between examiners. For PD and CAL measurements,
the calibration standards were as follows: ≥80% intra-examiner
agreement for PD ± 1 mm,≥75% inter-examiner agreement for
PD ± 1 mm, ≥95% intra-examiner reproducibility ± 2 mm for
both parameters, ≥65% intra-examiner agreement for CAL ±
1 mm, and ≥60% inter-examiner agreement for CAL ± 1 mm.
Examiners were calibrated before examining trial participants
and annually thereafter.
Although examiners were calibrated using percentage
agreement, we also computed Cohen's kappa statistics to
provide the reader with another measure of inter- and
intra-examiner agreement. For examiners meeting the pre-
specified standards, kappa values for inter-examiner agree-
ment (comparing each examiner to the single gold standard)
ranged from 0.75 to 1.00 for PD ± 1 mm, from 0.95 to 1.00
for PD ± 2 mm, from 0.63 to 1.00 for CAL ± 1 mm, and
from 0.89 to 1.00 for CAL ± 2 mm. Kappa values for intra-
examiner agreement ranged from 0.87 to 1.00 for PD ±
1 mm, were all 1.00 for PD ± 2 mm, ranged from 0.84 to
1.00 for CAL ± 1 mm and were all 1.00 for CAL ± 2 mm.
Kappa statistics were not computed for GI (the gingivitis
index) because the kappa statistic is sensitive to skewed
distributions, which is common for this index. Determining
bleeding on probing (BOP) is an invasive procedure and sites
are more likely to bleed at subsequent passes in a calibration
trial. Thus, valid calibration protocols for BOP do not exist.
Examiners were trained but not calibrated for the Plaque
Index because plaque is removed when this particular index
is scored [30].
2.8.3. Secondary outcomes: Insulin, glucose, and HOMA2
Insulin was measured in serum on a Roche Elecsys 2010
Analyzer (Roche Diagnostics Corp., Indianapolis, IN) using a
sandwich immunoassay method with a chemiluminescent
endpoint (Roche Diagnostics Corp.). The method is calibrated
against the 1st IRP WHO Reference Standard 66/304 (NIBSC).
The laboratory CV is 4.2%.
Glucose was measured in serum by the Roche hexoki-
nase method on a Roche Modular P Chemistry Analyzer
(Roche Diagnostics Corp.). The method is calibrated against
Standard Reference Material 965a from the National Insti-
tute of Standards and Technology (NIST). The laboratory CV
is 1.6%
HOMA2 values were determined from the insulin and
glucose measurements using the HOMA2 Calculator, version
2.2 (http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/).
HOMA2 values were calculated for non-insulin users with
fasting plasma glucose levels between 3.5 and 25.0 mmol/l and
fasting plasma insulin levels between 20 and 400 pmol/l.
2.8.4. Lipid panel and creatinine
Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol,
triglycerides and serum creatinineweremeasured or computed
to characterize the study population. Lipids and creatininewere
assayed by enzymatic methods using a Roche Modular P
Chemistry Analyzer. The Core Laboratory's cholesterol, HDL-
cholesterol and triglyceride calibrationmethods and results aremonitored by the CDC/NHLBI Lipid Standardization Program.
The laboratory's CV for the three lipid measures are 1.6%,
2.9% and 4.0%, respectively. The creatinine method is cali-
brated against NIST standard reference material SRM 967.
The laboratory CV for creatinine is 2.3%. LDL-cholesterol
was calculated using the formula of Friedewald et al. [33] if
triglycerides were b400 mg/dL.
2.8.5. Medication use and changes
Because diabetes medication changes were a secondary
trial outcome, Study Coordinators needed to accurately
record and monitor participants' medication use. To address
the challenges of tracking the sheer and growing number of
individual and combinatory hypoglycemic medications, we
instituted several protocols to assist the Coordinators to
record medications and dosages. First, physician investiga-
tors at each site reviewed medications reported at baseline
for accuracy and completeness, and at subsequent study
visits if questions arose about changes in drugs or dosing.
The Medical Monitor, the CC and a trial diabetologist (MG)
also developed a detailed glossary that included all FDA-
approved oral and injectable hypoglycemic agents, by generic
and brand name, and by formulation and dosing. Investigators
also used the National Library of Medicine's RxNorm (http://
www.nlm.nih.gov/research/umls/rxnorm/overview.html) to
provide standard coding for entering medications into Velos
eResearch.
2.9. Masking
Laboratory personnel and periodontal examiners were
masked to a participant's group assignment. Masking was
maintained using standard approaches. First, randomization
assignments by individual participant were accessible in
Velos eResearch only to the necessary CC personnel and the
Clinical Site Coordinators. Participant IDs did not contain
treatment assignment codes. Identical protocols and study
forms were used to collect data from both Treatment and
Control Group participants. Lastly, brief questionnaires
administered to examiners at the 6-month visit evaluated
whether the efforts to achieve masking of the periodontal
examiners were successful.
2.10. Randomization process
The CC confirmed a participant's eligibility after reviewing
the baseline and screening data. Randomization was con-
ducted centrally by the CC using a site-specific randomization
assignment sequence generated prior to the start of the
study. Assignments to the Treatment and Control Groups
were created through a custom computer program using a
permuted block randomization scheme stratified by Clinical
Site using block sizes of 2, 4 or 6. Once eligibility for an
individual was confirmed, the CC Study Coordinator generated
the randomization assignment electronically and notified the
Clinic Coordinator by email or fax. The Clinic Coordinator then
contacted theparticipantwith the treatment group assignment.
No other Clinical Site personnel other than the Study Therapist
were informed of the assignments.
For randomized participants under the regular care of a
dentist, a letter was sent informing the provider of their
522 S. Engebretson et al. / Contemporary Clinical Trials 36 (2013) 515–526patient's participation in the trial. Providers were asked not
to provide periodontal care or tooth cleanings until their
patient completed the trial. Participants could receive minor
non-periodontal dental care as needed. Participants without
a dentist of record were referred to one or more community
clinics to address any treatment needs that arose during the
trial.2.11. Intervention
All participants received structured oral hygiene and
healthy lifestyle instructions at the baseline, 3- and 6-month
study visits.2.11.1. Treatment Group
Participants randomized to the Treatment Group received
full-mouth supra- and subgingival scaling and root planing
(i.e., non-surgical treatment), which was completed using
hand and sonic or ultrasonic instruments. Certified study
therapists (licensed dentists or hygienists) completed the
treatment over two or more sessions, each lasting approxi-
mately 90 min, and within 42 days of randomization. Local
(injected) or topical anesthetics (e.g., lidocaine, benzocaine)
were used as needed. Treatment was continued until the
therapist and an independent examiner determined that the
teeth and roots were free of dental plaque and calculus
(tartar). Following each treatment visit, participants received
a 16-ounce bottle of an antimicrobial mouth rinse (Chlor-
hexidine Gluconate 0.12%, 0.5 oz rinse for 30 s twice daily).
The rinse is approved by the Food and Drug Administration
for reducing dental plaque and gingivitis and provides an
adjunctive benefit to scaling and root planing [34,35].
The intervention did not include systemic (peroral) anti-
biotics. Although antibiotics are useful adjuncts to mechan-
ical therapy in the treatment of aggressive periodontitis [36],
concerns about overall efficacy and gastrointestinal side
effects, and growing concerns about antibiotic resistance
contraindicate their routine use in chronic periodontitis
patients [37]. Systemic antibiotics, however, were allowed
as part of rescue treatment for Treatment Group participants
(Section 2.12.2).
We defined the intervention based on the length of treat-
ment and the achievement of complete plaque and calculus
removal. We did not define treatment endpoints, i.e., minimal
required improvements in selected clinical measures following
treatment. Although some have advocated for the use of such
endpoints [38], the minimal response needed to improve
glycemic control in patients with T2DM has not been deter-
mined. The periodontology community also lacks a consen-
sus regarding the definition of “successful” treatment in
terms of PD and BOP reductions [39]. Thus, we standardized
treatment by requiring therapists to be trained and certified,
by specifying a minimum length of treatment, and by
utilizing an independent examiner to verify complete plaque
and calculus removal.
As is convention in clinical practice, Treatment Group
participants also received full mouth scaling and polishing
(i.e., a cleaning), and localized root planing as needed, 3 and
6 months following randomization.2.11.2. Control Group (delayed treatment)
Control Group participants did not receive periodontal
treatment during the trial unless their condition deteriorated
(Section 2.12.2). Delaying treatment was not considered
unethical because of the low risk for disease progression over
6 months [40] and because these individuals were monitored
frequently and offered immediate (rescue) treatment if their
disease progressed. After completing their 6-month visits,
Control Group participants were offered the same treatment
provided to the Treatment Group.
2.12. Trial monitoring
2.12.1. Adverse event reporting
Trial monitoring and reporting of adverse events were
conducted in accordance with the Office for Human Research
Protections guidelines and under the auspices of the trial's
Medical Monitor. DPTT was a low risk study and serious
adverse events due to study participation were not expected.
Events that occurred within two weeks of completion of
therapy for the Treatment Group or within two weeks of the
baseline visit for the Control Group were considered as study
related and reported as adverse events. Serious or unantic-
ipated adverse events within this window were reported to
the local IRB as needed, to the Medical Monitor, and to the
Contract Research Organization (Rho, Inc.), acting on behalf
of the funding agency (NIDCR). Adverse events, expected or
otherwise, that occurred outside of the two-week window
were reported to the local IRBs as needed but were not
considered to be study-related.
Clinic Coordinators interviewed participants by phone two
weeks following the completion of treatment (for Treatment
Group participants) or the baseline examination (for Control
Group participants). Participants were given a diary card at the
baseline visit to aid in recognizing and recording adverse events
during this period. Participants were asked to record and report
oral bleeding, pain or swelling, temperature sensitivity, diffi-
culty chewing or eating, and signs and symptoms related to the
use of the chlorhexidine mouth rinse (e.g., tooth discoloration
and changes in taste). At each follow-up visit, study personnel
questioned participants regarding oral symptoms, newmedical
conditions and other possible study-related adverse events.
2.12.2. Monitoring for progressive periodontal disease
Examiners evaluated participants at 3 and 6 months for
periodontitis progression, defined as an increase in CAL of
N2 mm at any tooth site. Participants with five or fewer prog-
ressing sites received immediate treatment (scaling and root
planing) by study therapists on the affected teeth. Participants
with more than five progressing sites were considered to have
generalized progressive disease, treatment for these individuals
differed according to group assignment. Control Group partici-
pants received full-mouth scaling and root planning. Treatment
Group participants were referred to a consulting periodontist
and retreated with scaling and root planing. The periodontist
could supplement re-treatment with systemic (peroral) antimi-
crobials (e.g. Augmentin, metronidazole, or the combination of
both). The choice, and even use, of antibiotics was left up to the
discretion of the consulting periodontist. Rescue therapy was
administered as soon as possible after disease progression was
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independent assessment of the need for rescue therapy.
2.12.3. Diabetes safety monitoring
Although participantswere required to be under the care of a
physician, the trial took additional steps tomonitor theirmedical
safety. HbA1c values ≥9.5% at any study visit were communi-
cated in writing to the participant and to his or her physician.
Participants with evidence of symptomatic hypertension or
hyper- or hypoglycemia were referred for immediate medical
management. Participants also were informed about their
current blood pressure and weight at each visit.
2.12.4. Data and safety monitoring
An independent Data and Safety Monitoring Board (DSMB)
reviewed and approved the study protocol before implemen-
tation. The DSMB, which was appointed by the NIDCR and
included experts in periodontology, diabetology, biostatistics
and clinical trials methodology, provided advice to the NIDCR
concerning participant safety, data quality, and trial per-
formance. The Board reviewed monthly reports monitoring
routine study progress and annual reports detailing recruit-
ment, participant retention, trial safety, protocol adherence and
data quality. The Board also reviewed results from the planned
interim futility analysis (Section 2.14.2).
2.13. Quality assurance
Study activities were monitored internally by the Steering
Committee and externally by the DSMB. In collaboration
with the Study Chair, the CC developed and implemented
standards for training and certifying staff and examiners, by
study role. In addition, the CC reviewed incoming data and
generated data queries for the clinical sites, and communi-
cated regularly with study investigators and personnel to
identify and resolve procedural errors. The CC also prepared
reports detailing study progress and quality, which were
reviewed during monthly Steering Committee conference
calls. The study also implemented periodic site monitoring by
an independent quality assurance team acting in behalf of
NIDCR (Rho, Inc.)
2.14. Sample size and data analyses
2.14.1. Sample size
The study was powered to detect at least a 0.6% reduction
in HbA1c associated with periodontal treatment. We as-
sumed a 0.6% reduction in HbA1c in the Treatment Group, no
reduction in the Control Group, and a standard deviation
(SD) of 2.0% for the distribution of 6-month changes for both
groups. Sample size was estimated assuming a 5% type 1
error rate (alpha) and 90% (1- beta) power. The 0.6%
expected group difference was based on results of a meta-
analysis of five small studies that reported a weighted average
decrease in HbA1c of 0.66% associated with periodontal
treatment [17].
The estimated SD of the change in HbA1c was derived
from three sources: from the range of values reported in 10
small intervention studies [17], from the SD noted in an
unpublished pilot study conducted by the study chair, and
from a Veteran's Administration study of 132 participants[18]. The reported or calculated SDs for changes in these trials
ranged from 0.9 to 2.0%. Based on a two-tailed, two-sample
t-test and the above considerations, we estimated needing
baseline and 6-month data from 468 participants. Assuming a
20% attrition rate, we planned to randomize 600 participants
(300 in each study arm).
2.14.2. Futility analysis plan
One futility analysis was specified as part of the protocol to:
1) provide the probability, conditional on the interim observed
data, that the final data would demonstrate that periodontal
treatment lowers HbA1c level significantly more than no
treatment; and 2) allow early stopping of the trial for futility in
the absence of any treatment effect on the primary outcome. The
analysis was planned to be conducted after the first 300
randomized participants (50% of the recruitment goal) had
completed their six-month visit, which was estimated to occur
about 24 months after the start of enrollment. Predetermined
guidelines for determining futility to continue the study were
based on a two-sided, independent t-test and one-sided con-
ditional power calculated using the B-value proposed by Lan and
Wittes [41], again assuming a treatment group difference in
HbA1c of 0.60% and a within-group standard deviation of 2.0%.
2.14.3. Primary analysis
The primary outcome, 6-month change in HbA1c, will
be analyzed using use an intention-to-treat approach. A
last-observation-carried-forward imputation method will be
used for participants missing data from one or both follow-up
visits. The primary analysis will be based on a linear regression
model, with 6-month change inHbA1c as the response variable,
treatment assignment as a factor and adjusting for clinical site
as a covariate. The center effect was planned to be fixed. Clinical
site was included as a covariate to address potential center
differences in terms of the effect of periodontal therapy on the
study outcomes, HbA1c and periodontal disease. In addition,
the statistical analysis plan included ongoing monitoring of the
balance in baseline characteristics between study arms within
and between centers.
A secondary analysis will be conducted to evaluate
baseline characteristics as potential covariates (e.g. age,
gender, ethnicity, smoking status, BMI, diastolic blood
pressure, BOP and duration of diabetes) in a multivariable
regression model. Interactions between the above factors and
treatment status also will be explored. Sub-group analyses
will be performed to evaluate treatment effects on 6-month
change in HbA1c in different levels of covariates (e.g. in each
gender group). The same analytical strategy will be applied to
the clinical measures of chronic periodontitis (PD, CAL, BOP).
Additional secondary outcomes (e.g., fasting glucose, fasting
insulin, HOMA2 insulin resistance and HOMA2 β-cell func-
tion) will also be analyzed using linear regression models.
The association between each secondary outcome and the
periodontal measurements will be estimated using Pearson
or Spearman correlations.
3. Discussion
The exact mechanisms by which periodontal disease
and its treatment may affect glycemic control in patients with
T2DM have not been fully elucidated. A popular hypothesis
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geneses of periodontitis and insulin resistance [42]. Specifically,
interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-
alpha), which are present in inflamed periodontal tissues [43],
are known to adversely affect insulin signaling and action.
[44,45]. Both Il-6 and TNF-alpha may enter the systemic
circulation in patients with periodontitis, where over time
they may alter insulin sensitivity in target organs. Thus, it is
biologically plausible that periodontitis may exacerbate glyce-
mia in patients with T2DM and that treatment, by reducing
levels of circulating cytokines, may improve glycemic control.
The DPTT is the largest and only controlled multi-center
clinical trial designed to date to determine the effects of
periodontal treatment on glycemic control in individuals with
T2DM. Although a series of small trials suggest that non-surgical
periodontal treatment results in modest reductions in HbA1c,
data from large, multi-center trials, enrolling participants from
diverse populations, are needed to better inform the dental and
medical communities regarding the value of diagnosing and
treating periodontitis in this patient population. The DPTT will
help fill this important knowledge gap.
While the DPTT successfully built and sustained collabo-
rations across professions (medicine, dentistry, epidemiology
and biostatistics), it was not without its challenges. The same
trial needs that fostered the development of integrated yet
diverse study teams also challenged study personnel to
operate in unfamiliar clinical settings and environments.
Two challenges – recruitment and tracking medication use –
are discussed below in more detail.
T2DM and periodontitis are prevalent conditions that are
associated with one another. Thus, one might expect patients
with T2DM to frequently present with periodontitis, and
vice versa. The specific enrollment criteria for each disease,
however, limited the pool of potentially eligible DPTT partici-
pants. While most screened participants had some level of
periodontitis, enrollment was limited to those with moderate
to advanced untreated periodontitis and no essential dental
care needs. Over half of initially screened participants did not
meet the dental or periodontal enrollment criteria. Those with
essential dental care needs often needed to have extensively
decayed or abscessed teeth extracted before being rescreened
several months later. This slowed the enrollment process.
Recruitment also was challenging because T2DM and
periodontitis are managed within different care systems. Few
patients are “co-managed” across medicine and dentistry in a
manner that regularly occurs within each profession. Thus,
the trial was challenged to sustain collaborations between
medical and dental provider networks to access the appro-
priate patient populations. Our original goal was to complete
recruitment within 26 months. Even with the addition of two
clinical sites, however, the recruitment period was extended
for an additional 3 months.
Many participants were identified through primary care
or specialty medical (e.g., diabetes) clinics. Physicians and
their staff, however, are not routinely trained to recognize
periodontal disease. At some Clinical Sites, patients recruited
through medical clinics were screened by dental personnel
directly in the medical clinics and at the time of their medical
visits. Mostly, however, potentially eligible individuals were
referred to dental clinics for screening, which increased the
screening burden for these individuals.Potential participants also were identified through dental
record searches. Dental care providers, however, typically
do not record HbA1c values for their T2DM patients. Thus,
we could not identify through these records alone patients
who were likely to qualify for the trial. In addition, many
individuals identified through dental school records either
had unmet essential dental care needs or had received at
least some periodontal treatment. As a result, recruitment
efforts within dental school clinics were not consistently
fruitful.
Every Clinical Site struggled to optimize its recruitment
efforts. Study personnel across sites regularly exchanged
ideas through conference calls, emails and in-person meet-
ings. Each site eventually relied on a mix of shared and
unique recruitment strategies. A particularly effective ap-
proach was to encourage physicians at affiliated clinics to
send study invitations to patients that she or he believed
might be eligible for the trial. The IRB-approved introductory
letters provided a brief overview of the study and listed
several study phone numbers. Engaging physicians also may
have helped reassure patients that their physician is concerned
with their oral needs and that the trial was worthwhile. In
contrast, the effectiveness of broad-based recruitment efforts
(e.g., posted study fliers and brochures, radio advertisements)
varied substantially by Clinical Site. Overall, 29% of all screened
participants were randomized. Screening success, however,
ranged from 17% to 51% across clinical sites, which likely
reflected among-site differences in clinic patient characteristics
and recruitment strategies.
Despite pre-trial training, Study Coordinators frequently
had questions regarding drug names and dosing due to the
wide variability of both generic and brand name medications
with the same formulary. The problem was compounded by
the number of available individual and combinatory hypo-
glycemic medications, and because the Coordinators were
more experiencedwith dental than diabetes trials. To address
this challenge, we instituted several protocols, outlined in
Section 2.8.5, to assist the Coordinators in recording medica-
tion use and dosing changes. Although designed for comput-
er systems, use of RxNorm enabled investigators to track and
analyze drug information more efficiently and unambigu-
ously within and between participant records. The CC also
generated queries for medications and dosages that did not
match the dosing contained in the trial's drug glossary or that
were inconsistent across study visits. Finally, the Study
Coordinators received regular training updates on medica-
tion use during their bimonthly conference calls.
The DPTT was designed and initiated to address an
important topic in “periodontal medicine” and diabetes control.
Periodontal disease has been associated with a wide variety of
conditions including diabetes [42], adverse pregnancy outcomes
[46], cardiovascular disease [47], and certain cancers [48]. Much
of the evidence for these links comes fromobservational studies,
for which residual confounding by shared risk factors is a real
concern. Interventional studies, such as the DPTT, are needed
to better understand the nature of these associations. The
DPTT should provide ample evidence to support or refute the
hypothesis [47] that treatment of periodontal disease affects
glycemic control in patients with T2DM. The DPTT's approaches
to building and training multi-professional study teams, and to
applying broad and novel recruitment strategies, could be
525S. Engebretson et al. / Contemporary Clinical Trials 36 (2013) 515–526adopted by others studying new ways to manage patients with
multiple chronic disorders.
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